BioLineRx Ltd. (BLRX)
BLRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/0001178913-26-001581-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BLRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | Not reported by the screener |
| SEC CIK | 0001498403 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Israel |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.2M |
| Net income | -$2.0M |
| Operating income | -$10.3M |
| Net margin | -171.7% |
| Operating margin | -871.8% |
| Revenue growth | -95.9% |
| Cash | $3.3M |
| Total assets | $40.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Management has concluded that there is substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all." | 20-F 2026-03-23 |
| Cash and burn | $3.3M cash; operating cash flow -$2.0M a quarter. | Report 2025-12-31 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2026-03-08 |
| Reverse splits, 3 years | 1; latest 1-for-40 on 2025-01-30 | Source 2025-01-30 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-08-31 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Kesselman & Kesselman C.P.A.s, Tel-Aviv, Israel | PCAOB Form AP 2026-04-12 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $1.2M | -$2.0M | -$8.1M | $3.3M | $4.5M | $1.2M | 20-F 2026-03-23 |
| FY 2024 2024-12-31 | $28.9M | -$9.2M | -$43.9M | $10.4M | $4.5M | $28.9M | 20-F 2026-03-23 |
| FY 2023 2023-12-31 | $4.8M | -$60.6M | -$22.6M | $4.3M | $3.1M | $4.8M | 20-F 2026-03-23 |
| FY 2022 2022-12-31 | $0 | -$25.0M | -$26.2M | $10.6M | $1.5M | $0 | 20-F 2025-03-31 |
| FY 2021 2021-12-31 | $0 | -$27.1M | -$23.6M | $13.0M | $2.8M | $0 | 20-F 2024-03-26 |
| FY 2020 2020-12-31 | Not filed | -$30.0M | -$23.2M | $16.8M | $5.8M | Needs four quarters | 20-F 2023-03-22 |
| FY 2019 2019-12-31 | Not filed | -$25.4M | -$22.7M | $5.3M | $8.5M | Needs four quarters | 20-F 2022-03-16 |
| FY 2018 2018-12-31 | Not filed | -$23.0M | -$24.2M | $3.4M | $8.7M | Needs four quarters | 20-F 2021-02-23 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-10-02 |
| Latest annual report | 20-F | 2026-03-23 |
| Latest quarterly / interim | 6-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 619 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -24.0% |
| 1 month | -40.1% |
| 3 months | -52.2% |
| Year to date | -53.1% |
| 1 year | -62.5% |
| From 52-week high | -65.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ALZN | Alzamend Neuro Inc. | $1.18 | -4.84% | $5.7M |
| APRE | Aprea Therapeutics Inc. | $0.4063 | -2.38% | $5.8M |
| ACXP | Acurx Pharmaceuticals Inc. | $0.9350 | -2.60% | $5.7M |
| LTRN | Lantern Pharma Inc. | $0.3890 | -10.18% | $5.8M |
| FBLG | FibroBiologics Inc. | $0.9034 | -2.00% | $6.1M |
| JAGX | Jaguar Health Inc. | $0.3864 | -7.74% | $5.2M |
| TOVX | Theriva Biologics Inc. | $0.1400 | -2.85% | $6.4M |
| CNSP | CNS Pharmaceuticals Inc. | $3.48 | +20.42% | $5.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier